Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluR2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluR2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 2 mg/ml in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 1268.47. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.79 mL||3.94 mL||7.88 mL|
|5 mM||0.16 mL||0.79 mL||1.58 mL|
|10 mM||0.08 mL||0.39 mL||0.79 mL|
|50 mM||0.02 mL||0.08 mL||0.16 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Daw et al (2000) PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron 28 873 PMID: 11163273
Hanley et al (2002) NSF ATPase and α-/β-SNAPs disassemble the AMPA receptor-PICK1 complex. Neuron 34 53 PMID: 11931741
Kim et al (2001) Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc.Natl.Acad.Sci.U.S.A. 98 11725 PMID: 11573007
Li et al (1999) AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat.Neurosci. 2 972 PMID: 10526335
If you know of a relevant reference for pep2-AVKI, please let us know.
View Related Products by Product Action
Keywords: pep2-AVKI, supplier, Peptide, inhibitors, inhibits, GluR2, subunit, binding, PICK1, Glutamate, AMPA, Receptors, iGluR, Ionotropic, AMPA, Receptors, AMPA, Receptors, Tocris Bioscience
Citations for pep2-AVKI
Citations are publications that use Tocris products.
Currently there are no citations for pep2-AVKI. Do you know of a great paper that uses pep2-AVKI from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.